8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

December 17, 2009

Date of Report (date of earliest event reported)

SENORX, INC.

(Exact name of Registrant as specified in its charter)

Delaware	001-33382	33-0787406
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

3 Morgan, Irvine, California 92618

(Address of principal executive offices)

(949) 362-4800

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.  Other Events.

On December 17, 2009, a jury delivered a verdict in favor of SenoRx, Inc. (“SenoRx” or the “Company”) in a lawsuit brought by Hologic, Inc., Cytyc Corp., and Hologic L.P. (together “Hologic”) in the United States District Court, Northern District of California.  Hologic had alleged that SenoRx infringed claims of Hologic’s 6,413,204 and 6,482,142 patents. SenoRx claimed that both patents were invalid, and that the ‘204 patent was not infringed. The jury found that SenoRx was not liable for infringement of the ‘204 patent and that both patents were invalid.  A copy of the press release announcing the aforementioned verdict is furnished as Exhibit 99.1 to this Form 8-K and will be available on our website at www.senorx.com.

Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release of SenoRx, Inc. dated as of December 18, 2009.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SENORX, INC.
Date:  December 18, 2009	By:	/s/ Kevin J. Cousins
		Kevin J. Cousins
		Chief Financial Officer,Vice President, Finance

3

EX-99.1

Exhibit 99.1

Press Release

SENORX FOUND NOT LIABLE FOR PATENT INFRINGEMENT

IRVINE, Calif., December 18 – SenoRx, Inc. (Nasdaq:  SENO) today announced that a jury delivered a verdict in favor of SenoRx in a lawsuit brought by Hologic, Inc., Cytyc Corp., and Hologic L.P. (Hologic) in the U.S. District Court for the Northern District of California.  Hologic had alleged that SenoRx infringed claims of Hologic's 6,413,204 and 6,482,142 patents. SenoRx claimed that both patents were invalid, and that the '204 patent was not infringed.

The jury found that SenoRx was not liable for infringement of the ‘204 patent and that both patents were invalid.  Lloyd Malchow, SenoRx Chairman and Chief Executive Officer, said, “We are pleased with the jury’s verdict.  We have been steadfast from the beginning and confident in our position.  We look forward to focusing all of management’s time on continuing to develop innovative new products to assist and improve the medical community’s ability to diagnose and more effectively treat breast cancer.”

About SenoRx

SenoRx (NASDAQ: SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor® vacuum-assisted breast biopsy system and Contura™ MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer.  SenoRx’s field sales organization serves over 2,000 breast diagnostic and treatment centers in the United States and Canada.  In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company’s line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer.  For more information, visit the company’s website at www.senorx.com.

CONTACT:  SenoRx, Inc. Lila Churney, Director of Investor Relations 949-362-4800 x132